Stroke is the third leading cause of death in industrialized countries and the first cause of adult dependency. Identifying accurately its genetic determinants is a key issue in order to improve diagnosis and treatment strategies and to reduce its huge public health burden. From a clinical perspective, stroke genetics will probably make a great revolution in the near future. New technological tools and the resulting findings will permit the early recognition of people at risk of developing a stroke and therefore a better targeted prevention of the disease.

This knowledge will be used to test people with a possible genetic background (if one or a few familiars are affected), or with several clinical risk factors for stroke that could benefit from a more aggressive treatment of some of these risk factors. The predictive possibility of genetic testing will impact beneficially on the quality of life (e.g. to avoid or reduce the appearance of the disease), as well as on a financial level (e.g. to reduce the cost caused by expensive treatments). Pharmacogenetics and gene therapy could also develop from these results, leading to a new individualized therapy where physicians adapt their therapy in function of the genetic variability of their patients and thus improve the efficacy of the treatment while reducing the adverse drug reactions.

Because the results brought by these new technologies are very complex and difficult to combine, GenoKeys is dedicated to offer counselling to patients and professionals. A wide range of topics are covered by our team of specialists, including genetic, technical and medical issues. This service is not designed to only help using GenoKeys’ genetic testing tools, but also to give advice and counselling on any question related to the genetics of neurological diseases.